Vivesto (VIVE) Study result summary

Top-line findings

• In dogs, Paccal Vet doubled overall survival versus surgery alone.

• Preliminary results from all 21 enrolled cats showed anti-tumor effects across multiple tumor types and dose levels.

• Best biological responses were observed in 15 cats: 1 complete response, 6 partial responses and 8 cases of stable disease for at least six weeks.

• Dog and cat study results supported safety and tolerability, with no hypersensitivity reactions observed.

• Current dog-study findings build on prior exposure of more than 300 dogs to the compound.

Safety and tolerability

• In cats, side effects included decreased appetite, lethargy and neutropenia; they were mostly mild, temporary and manageable with supportive medication.

Clinical potential

• For splenic hemangiosarcoma, Paccal Vet could serve dogs unable to safely receive doxorubicin or as an option after doxorubicin failure.

• Anti-cancer responses across feline tumor types, some within days, address limited standard options and unmet need in feline oncology.

• The first feline trial achieved doses higher than in a previous study of conventional human paclitaxel, informing future dose selection.